Comparing end-of-life care of hematologic malignancy versus solid tumor patients in a tertiary care center.

Rachel BursteinAriel AvivNoa Gross Even-ZoharBoaz NachmiasArnon HaranMichal BraunYakir RottenbergAdir Shaulov

Published in: European journal of haematology (2023)

HM patients were more likely than solid tumor patients to undergo aggressive measures at EOL. Rarity of HM deaths, frequently caused by complications of treatment and unrelated causes, may affect treatment choices at EOL.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
tertiary care
patient reported